“Eight mainland China-based companies – five of them biotech firms – passed listing hearings on the Hong Kong stock market in April, clearing the way for them to tap the city’s deep liquidity. The influx, including an AI-driven drug discovery firm, a driverless technology developer and a maker of industrial robots, comes as the China Securities Regulatory Commission (CSRC) has been pushing private firms to list in Hong Kong. The market regulator has required companies that established so-called...
Original story
Continue reading at SCMP Hong Kong
www.scmp.com/news/hong-kong
Summary generated from the RSS feed of SCMP Hong Kong. All article rights belong to the original publisher. Click through to read the full piece on www.scmp.com/news/hong-kong.